182 related articles for article (PubMed ID: 35499071)
21. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
22. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
23. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
Takaki H; Hirata Y; Ueshima E; Kodama H; Matsumoto S; Wada R; Suzuki H; Nakasho K; Yamakado K
J Vasc Interv Radiol; 2020 Sep; 31(9):1475-1482.e2. PubMed ID: 32800663
[TBL] [Abstract][Full Text] [Related]
24. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
25. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.
Koh J; Jang JY; Keam B; Kim S; Kim MY; Go H; Kim TM; Kim DW; Kim CW; Jeon YK; Chung DH
Oncoimmunology; 2016 Mar; 5(3):e1108514. PubMed ID: 27141364
[TBL] [Abstract][Full Text] [Related]
26. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
27. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Koh YW; Lee SJ; Han JH; Haam S; Jung J; Lee HW
Lung Cancer; 2019 Mar; 129():41-47. PubMed ID: 30797490
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
30. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
31. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
32. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
33. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J
PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576
[TBL] [Abstract][Full Text] [Related]
34. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
35. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Zhao Y; Wang XX; Wu W; Long H; Huang J; Wang Z; Li T; Tang S; Zhu B; Chen D
Biochem Biophys Res Commun; 2019 Sep; 517(2):201-209. PubMed ID: 31331645
[TBL] [Abstract][Full Text] [Related]
36. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
37. Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior.
Pinato DJ; Black JR; Trousil S; Dina RE; Trivedi P; Mauri FA; Sharma R
Oncoimmunology; 2017; 6(11):e1358332. PubMed ID: 29147618
[TBL] [Abstract][Full Text] [Related]
38. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
39. The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy.
Mortezaee K; Majidpoor J; Kharazinejad E
Biomed Pharmacother; 2023 Jun; 162():114646. PubMed ID: 37011483
[TBL] [Abstract][Full Text] [Related]
40. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.
Messeha SS; Zarmouh NO; Soliman KFA
Nutrients; 2021 May; 13(5):. PubMed ID: 34069461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
